Could FiLaC™ be effective in the treatment of anal fistulas? A systematic review of observational studies and proportional meta‐analysis

Aim Fistula Laser Closure (FiLaC™) is a novel sphincter‐preserving technique that is based on new technologies and shows promising results in repairing anal fistulas whilst maintaining external sphincter function. The aim of the present meta‐analysis is to present the efficacy and the safety of FiLa...

Full description

Saved in:
Bibliographic Details
Published in:Colorectal disease 2020-12, Vol.22 (12), p.1874-1884
Main Authors: Frountzas, M., Stergios, K., Nikolaou, C., Bellos, I., Schizas, D., Linardoutsos, D., Kontzoglou, K., Vaos, G., Williams, A. B., Toutouzas, K.
Format: Article
Language:English
Subjects:
Adipose tissue
anal
Clinical trials
Collagen (type I)
Fibrin
FiLaC
Fistula
Fistulae
Meta-analysis
Observational studies
Quality of life
Sphincter
treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim Fistula Laser Closure (FiLaC™) is a novel sphincter‐preserving technique that is based on new technologies and shows promising results in repairing anal fistulas whilst maintaining external sphincter function. The aim of the present meta‐analysis is to present the efficacy and the safety of FiLaC™ in the management of anal fistula disease. Method The present proportional meta‐analysis was designed using the PRISMA and AMSTAR guidelines. We searched MEDLINE, Scopus, clinicaltrials.gov, Embase, Cochrane Central Register of Controlled Trials CENTRAL and Google Scholar databases from inception until November 2019. Results Overall, eight studies were included that recruited 476 patients. The pooled success rate of the technique was 63% (95% CI 50%–75%). The pooled complication rate was 8% (95% CI 1%–18%). Sixty‐six per cent of patients had a transsphincteric fistula and 60% had undergone a previous surgical intervention, mainly the insertion of a seton (54%). The majority had a cryptoglandular fistula. Operation time and follow‐up period were described for each study. Conclusion FiLaC™ seems to be an efficient therapeutic option for perianal fistula disease with an adequate level of safety that preserves quality of life. Nevertheless, randomized trials need to be designed to compare FiLaC™ with other procedures for the management of anal fistulas such as ligation of intersphincteric fistula tract, anal advancement flaps, fibrin glue, collagen paste, autologous adipose tissue, fistula plug and video‐assisted anal fistula treatment.
ISSN:1462-8910
1463-1318
DOI:10.1111/codi.15148